Safety and efficacy of a tCD25 preselective combination anti-HIV lentiviral vector in human hematopoietic stem and progenitor cells

Sharlie L. Barclay, Yimin Yang, Siruo Zhang, Ryan Fong, Alfonso Barraza, Jan Nolta, Bruce E. Torbett, Mehrdad Abedi, Gerhard Bauer, Joseph S Anderson

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The successful suppression of human immunodeficiency virus (HIV) in the "Berlin Patient" has highlighted the ability of HIV-resistant hematopoietic stem cells to offer a potential functional cure for HIV-infected patients. HIV stem cell gene therapy can mimic this result by genetically modifying a patient's own cells with anti-HIV genes. Previous attempts of HIV gene therapy have been hampered by a low percentage of transplanted HIV-resistant cells which has led to minimal clinical efficacy. In our current study, we have evaluated the in vitro and in vivo safety and efficacy of a truncated/mutated form of human CD25 preselective anti-HIV lentiviral vector in human hematopoietic stem cells. This preselective vector allows us to purify vector-transduced cells prior to transplantation so an increased percentage of gene-modified cells can be delivered. Here, we demonstrate the safety of this strategy with successful engraftment and multilineage hematopoiesis of transduced cells in a humanized NOD-RAG1-/-IL-2rγ-/- knockout mouse model. Efficacy was also demonstrated with significant protection from HIV-1 infection including maintenance of human CD4+ cell levels and a decrease in HIV-1 plasma viremia. Collectively, these results establish the utility of this HIV stem cell gene therapy strategy and bring it closer to providing a functional cure for HIV-infected patients. Stem Cells 2015;33:870-879

Original languageEnglish (US)
Pages (from-to)870-879
Number of pages10
JournalStem Cells
Volume33
Issue number3
DOIs
StatePublished - Mar 1 2015

Fingerprint

Hematopoietic Stem Cells
HIV
Safety
Genetic Therapy
Stem Cells
Cell- and Tissue-Based Therapy
HIV-1
Viremia
Hematopoiesis
Berlin
Virus Diseases
Knockout Mice
Genes
Transplantation

Keywords

  • Gene therapy
  • Hematopoietic cells
  • Human immunodeficiency virus
  • Lentiviral vector

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology
  • Molecular Medicine

Cite this

Safety and efficacy of a tCD25 preselective combination anti-HIV lentiviral vector in human hematopoietic stem and progenitor cells. / Barclay, Sharlie L.; Yang, Yimin; Zhang, Siruo; Fong, Ryan; Barraza, Alfonso; Nolta, Jan; Torbett, Bruce E.; Abedi, Mehrdad; Bauer, Gerhard; Anderson, Joseph S.

In: Stem Cells, Vol. 33, No. 3, 01.03.2015, p. 870-879.

Research output: Contribution to journalArticle

Barclay, Sharlie L. ; Yang, Yimin ; Zhang, Siruo ; Fong, Ryan ; Barraza, Alfonso ; Nolta, Jan ; Torbett, Bruce E. ; Abedi, Mehrdad ; Bauer, Gerhard ; Anderson, Joseph S. / Safety and efficacy of a tCD25 preselective combination anti-HIV lentiviral vector in human hematopoietic stem and progenitor cells. In: Stem Cells. 2015 ; Vol. 33, No. 3. pp. 870-879.
@article{b84d1067ef7940849d7848252cc70723,
title = "Safety and efficacy of a tCD25 preselective combination anti-HIV lentiviral vector in human hematopoietic stem and progenitor cells",
abstract = "The successful suppression of human immunodeficiency virus (HIV) in the {"}Berlin Patient{"} has highlighted the ability of HIV-resistant hematopoietic stem cells to offer a potential functional cure for HIV-infected patients. HIV stem cell gene therapy can mimic this result by genetically modifying a patient's own cells with anti-HIV genes. Previous attempts of HIV gene therapy have been hampered by a low percentage of transplanted HIV-resistant cells which has led to minimal clinical efficacy. In our current study, we have evaluated the in vitro and in vivo safety and efficacy of a truncated/mutated form of human CD25 preselective anti-HIV lentiviral vector in human hematopoietic stem cells. This preselective vector allows us to purify vector-transduced cells prior to transplantation so an increased percentage of gene-modified cells can be delivered. Here, we demonstrate the safety of this strategy with successful engraftment and multilineage hematopoiesis of transduced cells in a humanized NOD-RAG1-/-IL-2rγ-/- knockout mouse model. Efficacy was also demonstrated with significant protection from HIV-1 infection including maintenance of human CD4+ cell levels and a decrease in HIV-1 plasma viremia. Collectively, these results establish the utility of this HIV stem cell gene therapy strategy and bring it closer to providing a functional cure for HIV-infected patients. Stem Cells 2015;33:870-879",
keywords = "Gene therapy, Hematopoietic cells, Human immunodeficiency virus, Lentiviral vector",
author = "Barclay, {Sharlie L.} and Yimin Yang and Siruo Zhang and Ryan Fong and Alfonso Barraza and Jan Nolta and Torbett, {Bruce E.} and Mehrdad Abedi and Gerhard Bauer and Anderson, {Joseph S}",
year = "2015",
month = "3",
day = "1",
doi = "10.1002/stem.1919",
language = "English (US)",
volume = "33",
pages = "870--879",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "3",

}

TY - JOUR

T1 - Safety and efficacy of a tCD25 preselective combination anti-HIV lentiviral vector in human hematopoietic stem and progenitor cells

AU - Barclay, Sharlie L.

AU - Yang, Yimin

AU - Zhang, Siruo

AU - Fong, Ryan

AU - Barraza, Alfonso

AU - Nolta, Jan

AU - Torbett, Bruce E.

AU - Abedi, Mehrdad

AU - Bauer, Gerhard

AU - Anderson, Joseph S

PY - 2015/3/1

Y1 - 2015/3/1

N2 - The successful suppression of human immunodeficiency virus (HIV) in the "Berlin Patient" has highlighted the ability of HIV-resistant hematopoietic stem cells to offer a potential functional cure for HIV-infected patients. HIV stem cell gene therapy can mimic this result by genetically modifying a patient's own cells with anti-HIV genes. Previous attempts of HIV gene therapy have been hampered by a low percentage of transplanted HIV-resistant cells which has led to minimal clinical efficacy. In our current study, we have evaluated the in vitro and in vivo safety and efficacy of a truncated/mutated form of human CD25 preselective anti-HIV lentiviral vector in human hematopoietic stem cells. This preselective vector allows us to purify vector-transduced cells prior to transplantation so an increased percentage of gene-modified cells can be delivered. Here, we demonstrate the safety of this strategy with successful engraftment and multilineage hematopoiesis of transduced cells in a humanized NOD-RAG1-/-IL-2rγ-/- knockout mouse model. Efficacy was also demonstrated with significant protection from HIV-1 infection including maintenance of human CD4+ cell levels and a decrease in HIV-1 plasma viremia. Collectively, these results establish the utility of this HIV stem cell gene therapy strategy and bring it closer to providing a functional cure for HIV-infected patients. Stem Cells 2015;33:870-879

AB - The successful suppression of human immunodeficiency virus (HIV) in the "Berlin Patient" has highlighted the ability of HIV-resistant hematopoietic stem cells to offer a potential functional cure for HIV-infected patients. HIV stem cell gene therapy can mimic this result by genetically modifying a patient's own cells with anti-HIV genes. Previous attempts of HIV gene therapy have been hampered by a low percentage of transplanted HIV-resistant cells which has led to minimal clinical efficacy. In our current study, we have evaluated the in vitro and in vivo safety and efficacy of a truncated/mutated form of human CD25 preselective anti-HIV lentiviral vector in human hematopoietic stem cells. This preselective vector allows us to purify vector-transduced cells prior to transplantation so an increased percentage of gene-modified cells can be delivered. Here, we demonstrate the safety of this strategy with successful engraftment and multilineage hematopoiesis of transduced cells in a humanized NOD-RAG1-/-IL-2rγ-/- knockout mouse model. Efficacy was also demonstrated with significant protection from HIV-1 infection including maintenance of human CD4+ cell levels and a decrease in HIV-1 plasma viremia. Collectively, these results establish the utility of this HIV stem cell gene therapy strategy and bring it closer to providing a functional cure for HIV-infected patients. Stem Cells 2015;33:870-879

KW - Gene therapy

KW - Hematopoietic cells

KW - Human immunodeficiency virus

KW - Lentiviral vector

UR - http://www.scopus.com/inward/record.url?scp=84923248072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923248072&partnerID=8YFLogxK

U2 - 10.1002/stem.1919

DO - 10.1002/stem.1919

M3 - Article

C2 - 25524029

AN - SCOPUS:84923248072

VL - 33

SP - 870

EP - 879

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 3

ER -